Summary by Futu AI
On December 31, 2023, Altimmune Inc. was the subject of a Schedule 13G filing with the United States Securities and Exchange Commission (SEC), indicating a change in ownership by certain entities and individuals. The filing was made under Rule 13d-1(c), which is used for persons who have acquired beneficial ownership of more than 5% of a class of equity securities of a public company. The entities and individuals listed in the filing include Avidity Partners Management LP, Avidity Partners Management (GP) LLC, Avidity Capital Partners Fund (GP) LP, Avidity Capital Partners (GP) LLC, Avidity Master Fund LP, David Witzke, and Michael Gregory. All parties reported owning 0 shares and thus, 0.0% of the class of common stock of Altimmune Inc. The filing also indicated that as...Show More